Navigation Links
Gerresheimer Expands in the Global Pharmaceutical Plastic Business
Date:9/22/2009

DUSSELDORF, Germany, September 22 /PRNewswire-FirstCall/ -- The Gerresheimer Group expands its activities in the pharmaceutical plastic business with two strategically significant investments in the USA and Europe. This week the company is almost simultaneously opening a new research and development center for medical plastic systems in the USA as well as a new production center for pharmaceutical plastic packaging in Spain. "Plastics are increasingly gaining in importance within our highly specialized service portfolio for the international pharmaceutical industry," Gerresheimer AG CEO Dr. Axel Herberg says. "The pharmaceutical plastic business has meanwhile become the division with the highest growth rate, which we are continu-ing to expand systematically. These are crucial investments in the Gerresheimer Group's growth."

The new technological center in Peachtree City (Georgia/USA) is opening up a new dimension for the Group's flourishing business with American industrial clients from the pharmaceutical, diagnostics and medical technology industry. As a full service provider for medical plastic systems, Gerresheimer has upgraded the US location, which has until recently been limited to manufacturing, to become a comprehensively operating research, development and production center. In the American market the Group now has facilities at the front end of its customized serial production of entire product and process development comparable to those only available in Europe up to now. The product range in this field includes highly developed inhalation systems for the treatment of respiratory diseases as well as insulin pen systems, skin-prick aids and lancets for the diabetes sector, which is also growing steadily.

The newly opened plant in Masalaves in Spain (region of Valencia) is also highly significant with regard to the broad market of standardized pharmaceutical system packaging made of plastics. The plant is deemed to be the biggest production center of its kind in Southern Europe and is a significant strategic base for Gerresheimer there as well as in the Central European region. Pharmaceutical bottles and multifunctional dosage and closure systems, for example for eye drops, contact lens care products, nose sprays as well as tablets, are being produced there.

With the help of significant acquisitions, targeted investments and organic growth Gerresheimer has accelerated its plastics business during the past five years and developed it into an internationally leading market force. All in all, the company now possesses 15 locations in Europe, America and Asia in this sector. Both segments of the plastics division are continuing to attain above average growth rates. Accounting for a third of group sales, plastics have already become the largest growth area within the Gerresheimer Group.

About Gerresheimer

Gerresheimer employs around 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totaled EUR1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.

    Contact Press:
    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax   +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.co

    Contact Investor Relations:
    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax   +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Standard & Poors Confirms Rating for Gerresheimer
2. Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed
3. Gerresheimer Continues Expansion Course
4. Blackstone Sells Gerresheimer Stake
5. Standard & Poors Raises Gerresheimer Rating to BB+
6. Gerresheimer Starts the Year Successfully in 2008
7. Gerhard Schulze New Chairman of the Supervisory Board of Gerresheimer AG
8. Gerresheimer Finalises Purchase of Spanish Company EDP
9. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
10. Linnartz New Head of Investor Relations of Gerresheimer
11. Growth Trend for Gerresheimer Continues Unabated - Debt Reduction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is ... Côté has 20+ years of experience within the beauty industry, ranging from marketing, ... array of high-end cosmetic brands, retail brands and outlets in Canada and New ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... Economics Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis ... (IRR) field. Offering practical takeaways to apply immediately to IRR programs, the report ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... North American CAREGiverSM of the Year for her extraordinary compassion and lifelong dedication ... 60,000 North American professional caregivers for the prestigious award each year – identifying ...
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in the ... water-related accidents and drownings during the summer. While most of us assume this type ... occur every day. Very few people are taking the time to learn how to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... AMSTERDAM , April 20, 2017  AbbVie ... that 99 percent (n=145/146) of chronic hepatitis C ... 4, 5 or 6 and compensated cirrhosis (Child-Pugh ... post-treatment (SVR 12 ) with its investigational, pan-genotypic ... rates were seen following 12 weeks of ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology: